McKesson Corporation (LON:0JZU)
London
· Delayed Price · Currency is GBP · Price in USD 661.70
+1.52 (0.23%)
At close: Aug 13, 2025
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Other | 11.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions | 11.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Growth | 1.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical | 327.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Growth | 22.12% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions | 5.22B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Growth | 13.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International | 14.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Growth | 2.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 11.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 11.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Other | 15.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Capital Expenditures | 163.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 15.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Capital Expenditures | 241.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Capital Expenditures | 11.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Capital Expenditures | 107.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 15.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Other | -522.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 343.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -522.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 343.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Operating Profit | 773.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Operating Profit Growth | -11.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -522.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 343.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Operating Profit | 4.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Operating Profit Growth | 44.09% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Operating Profit | 875.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Operating Profit Growth | 14.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Operating Profit | -213.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Operating Profit Growth | -159.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|